The results showed an increased LC3II/LC3I ratio, PINK1 and Parkin expression in the group treated with ovarian cancer cell-derived EVs when compared to that treated with normal ovarian cell-derived EVs. The gene discussed is PRKN; the disease is ovarian carcinoma.